A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome.
Alberto MartiniJoanna WangNicholas M BrownShivaram CumarasamyJohn P SfakianosArdeshir R RastinehadKenneth G HainesNils Peter WiklundSujit S NairAshutosh K TewariPublished in: BJU international (2019)
Our studies have elucidated unique genomic features of TP5, whilst confirming previous clinical findings that patients harbouring TP5 tend to have worse prognosis. This is the first RNA-based study to investigate the molecular diversity of TP5 and the first correlating CDKN2B to poorer prognosis in patients with prostate cancer.